MEDI-528, now recognized as enokizumumab, represents a groundbreaking treatment targeting the IGF1R, a vital protein implicated in multiple skin diseases . Early clinical data suggest considerable potential for the control of substantial atopic dermatitis , particularly in patients who have failed conventional therapies . This monoclonal antibody d